Nintedanib in patients with progressive fibrosing ILDs in subgroups by comorbidity burden

E. Bendstrup (Aarhus, Denmark), T. Moua (Rochester, MN, United States), M. Okamoto (Kurume, Japan), S. Tomassetti (Florence, Italy), C. Valenzuela (Madrid, Spain), W. Wuyts (Leuven, Belgium), C. Miede (Sulzbach (Taunus), Germany), D. Lievens (Ingelheim am Rhein, Germany), F. Bonella (Essen, Germany)

Source: International Congress 2022 – Comorbidities and symptoms in interstitial lung diseases think out of the box

Session: Comorbidities and symptoms in interstitial lung diseases think out of the box
Session type: Thematic Poster
Number: 1149

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Bendstrup (Aarhus, Denmark), T. Moua (Rochester, MN, United States), M. Okamoto (Kurume, Japan), S. Tomassetti (Florence, Italy), C. Valenzuela (Madrid, Spain), W. Wuyts (Leuven, Belgium), C. Miede (Sulzbach (Taunus), Germany), D. Lievens (Ingelheim am Rhein, Germany), F. Bonella (Essen, Germany). Nintedanib in patients with progressive fibrosing ILDs in subgroups by comorbidity burden. 1149

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.